Prevalence of HTLV-I antibody among two distinct ethnic groups inhabiting the Amazon region of Brazil. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Prevalence of HTLV-I antibody among two distinct ethnic groups inhabiting the Amazon region of Brazil.

Rev Inst Med Trop Sao Paulo. 1992 Jul-Aug;34(4):323-8. Unique Identifier : AIDSLINE MED/94098150
Nakauchi CM; Maruyama K; Kanzaki LI; Linhares AC; Azevedo VN; Fukushima T; Miyauchi M; Koshikawa N; Tamayama C; Mochizuki S; et al; Instituto Evandro Chagas, Fundacao Nacional de Saude, Belem,; Para, Brasil.

Abstract: HTLV-I seroprevalences of 3.63% (02/55), 12.19% (10/82) and 13.88% (10/72) were demonstrated among Tiryio, Mekranoiti and Xicrin Amazonian Indians, respectively, by the Western blotting enzyme assay (WBEI). By indirect immunoelectron microscopy (IIEM), 2 Tiriyo, 9 Mekranoiti and 6 Xicrin Amerindians were reactive. Of 44 serum samples from Japanese immigrants, none reacted by any of the techniques before mentioned. One, 8 and 6 serum samples from Tiryio, Mekranoiti and Xicrin Indians, respectively, were both WBEI and IIEM positive. Our results strongly suggest that HTLV-I and/or an HTLV-I antigenic variant circulate (s) among populations living in the Amazon region of Brazil.
Keywords: *Aborigines/STATISTICS & NUMER DATA Blotting, Western Brazil/EPIDEMIOLOGY Comparative Study Human HTLV-I Antibodies/*BLOOD HTLV-I Infections/*ETHNOLOGY/*IMMUNOLOGY Immunohistochemistry *Indians, South American/STATISTICS & NUMER DATA Japan/ETHNOLOGY Microscopy, Immunoelectron Prevalence Seroepidemiologic Methods JOURNAL ARTICLEKWDaborigines/statistics&numerdatablotting,westernbrazil/epidemiologycomparativestudyhumanhtlv-iantibodies/KWDbloodhtlv-iinfections/KWDethnology/KWDimmunologyimmunohistochemistryKWDindians,southamerican/statistics&numerdatajapan/ethnologymicroscopy,immunoelectronprevalenceseroepidemiologicmethodsjournalarticle
940430
M9440889

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .